Clinical Trial Update: Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD [Phase 2, Phase 3]

View source ↗

Summary

Aptinyx evaluated 50 mg NYX-783 daily for PTSD in phase 2/3 trials; the study status is terminated, with safety and efficacy data available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• NYX-783

Snippet

Sponsor: Aptinyx | Conditions: PTSD | Phase 2, Phase 3 | Status: TERMINATED